Pharmaids Pharmaceuticals (524572) Q1 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, were approved by the Board and reviewed by statutory auditors.

• The company operates in a single segment: Contract Research and Manufacturing Services.

Financial highlights

• Standalone revenue from operations for Q1 FY26 was Rs. 111.53 lakhs, down from Rs. 146.25 lakhs in Q4 FY25 and Rs. 113.93 lakhs in Q1 FY25.

• Standalone net loss for Q1 FY26 was Rs. 436.30 lakhs, compared to a net loss of Rs. 305.64 lakhs in Q4 FY25 and Rs. 162.34 lakhs in Q1 FY25.

• Consolidated revenue from operations for Q1 FY26 was Rs. 666.36 lakhs, up from Rs. 476.80 lakhs in Q4 FY25 and Rs. 473.07 lakhs in Q1 FY25.

• Consolidated net loss for Q1 FY26 was Rs. 531.53 lakhs, compared to a net loss of Rs. 480.31 lakhs in Q4 FY25 and Rs. 312.45 lakhs in Q1 FY25.

• Basic and diluted EPS (consolidated) for Q1 FY26 stood at Rs. (1.41), compared to Rs. (1.11) in Q4 FY25 and Rs. (0.76) in Q1 FY25.

Outlook and guidance

• Management and auditors confirm that the disinvestment of Anugraha Chemicals does not affect the financial position or performance for the period ending June 30, 2025.